Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 551 - 600 of 1868 results
- A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas.
- Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
- Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
- Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
- Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
- A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
- Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
- A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
- Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor.
- Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu.
- Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
- Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer.
- A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
- Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
- Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
- Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
- A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.
- Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
- Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
- Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
- A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
- A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
- An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
- Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.
- The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
- Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma.
- Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
- Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes.
- Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
- Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
- Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells.
- Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
- Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression.
- Antibody-mediated p53 protein therapy prevents liver metastasis in vivo.
- Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
- An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.
- Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
- Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines.
- Virus-specific CD8+ T cells in the liver: armed and ready to kill.
- Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
- Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
- Immunotherapy of tumors with neuroimmune ligand capsaicin.
- Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
- Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.
- Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
- Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.
- Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
- Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
- Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
- Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma.